A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

Trial Profile

A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy of the Parkinsonian Subtype (MSA-P)

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Multiple system atrophy; Parkinsonian disorders
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 30 Jun 2012 Planned end date changed from 17 Nov 2012 to 8 Dec 2012 as reported by European Clinical Trials Database record.
    • 23 Jun 2012 Planned number of patients changed from 140 to 243 as reported by European Clinical Trials Database record.
    • 23 Jun 2012 Additional location (Spain) added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top